ClinicalTrials.gg
Not yet recruitingNCT07585565Updated May 13, 2026

A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations

A Phase 2 interventional study of GM1 and GM1 in Parkinson's Disease, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. A total of 276 eligible Parkinson's disease participants with motor fluctuations will be enrolled and assigned to one of three cohorts. Within each cohort, participants will be randomized in a 3:1 ratio to receive either GM1 or matching placebo, resulting in six groups: Cohort 1 GM1 (n=69), Cohort 1 Placebo (n=23); Cohort 2 GM1 (n=69), Cohort 2 Placebo (n=23); Cohort 3 GM1 (n=69), Cohort 3 Placebo (n=23). All participants will continue their pre-enrollment anti-Parkinson's medication regimen as background therapy, which should remain as stable as possible during the study. The study consists of a 28-day screening period and an 85-day double-blind treatment period.

02

Conditions studied

  • Parkinson's Disease

Browse trials for

03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

This study's planned enrollment of 276 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 30 years at screening.
  2. Clinical diagnosis of clinically established or clinically probable Parkinson's disease.
  3. Currently receiving levodopa therapy (stable regimen for ≥4 weeks prior to randomization, with a levodopa equivalent daily dose ≥400 mg) and experiencing motor fluctuations (including wearing-off, on-off phenomena, etc.).
  4. Hoehn-Yahr stage ≥2 in the "OFF" state.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of other Parkinsonian syndromes or Parkinson-plus syndromes, or hereditary neurodegenerative disorders.
  2. Diagnosis of Parkinson's disease dementia or severe cognitive impairment as judged by the investigator at screening.
  3. Prior surgical treatment for Parkinson's disease or planned such surgery during the trial period.
  4. History or presence of other neurological diseases.
  5. History or presence of diseases.
  6. History or presence of any demyelinating diseases, including but not limited to acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome).
  7. History or presence of hereditary glycolipid metabolism disorders .
  8. Known allergy to monosialotetrahexosylganglioside sodium or any of the product.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    Cohort 1 GM1

    Drug: GM1

  • Placebo comparator
    Cohort 1 Placebo

    Drug: Placebo

  • Experimental
    Cohort 2 GM1

    Drug: GM1

  • Placebo comparator
    Cohort 2 Placebo

    Drug: Placebo

  • Experimental
    Cohort 3 GM1

    Drug: GM1

  • Placebo comparator
    Cohort 3 Placebo

    Drug: Placebo

Interventions

  • DrugG(M1) GangliosideStudies of G(M1) GangliosideG(M1) Ganglioside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1000 mg on Day 1, followed by 400 mg once daily from Day 2 to the end of Week 2, then a 2-week drug holiday.

  • DrugG(M1) GangliosideStudies of G(M1) GangliosideG(M1) Ganglioside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1000 mg on Day 1, followed by 200 mg once daily from Day 2 to the end of Week 2, then a 2-week drug holiday.

  • DrugG(M1) GangliosideStudies of G(M1) GangliosideG(M1) Ganglioside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1000 mg on Day 1, followed by 200 mg once daily from Day 2 to the end of Week 2. From Week 3 onward, 1000 mg once weekly until the last dose on Day 78.

  • DrugPlacebo

    1000 mg on Day 1, followed by 400 mg once daily from Day 2 to the end of Week 2, then a 2-week drug holiday.

  • DrugPlacebo

    1000 mg on Day 1, followed by 200 mg once daily from Day 2 to the end of Week 2, then a 2-week drug holiday.

  • DrugPlacebo

    1000 mg on Day 1, followed by 200 mg once daily from Day 2 to the end of Week 2. From Week 3 onward, 1000 mg once weekly until the last dose on Day 78.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total "ON" Time without Troublesome Dyskinesia as assessed by 24-hour patient diary cards.

    Time frame: Baseline, Day 85

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2028, 22 months later.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 22 months is above that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 13, 2026
StartEst.
May 2026
Primary completionEst.
Mar 2028
CompletionEst.
Aug 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07585565
Responsible party
Sponsor
First posted
May 13, 2026
Start date
May 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
May 13, 2026

Study contacts

Tao Feng
Contact
happyft@sina.com
+86 13911125339

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: G(M1) Ganglioside

Start the discussion